Medicare Enrolled

Dr. Arash Rezazadeh Kalebasty, M.D.

Hematology & Oncology · Orange, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
101 THE CITY DR S BLDG 23, Orange, CA 92868
7144568000
In practice since 2007 (19 years)
NPI: 1205974755 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Rezazadeh Kalebasty from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rezazadeh Kalebasty? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Rezazadeh Kalebasty

Dr. Arash Rezazadeh Kalebasty is a hematology & oncology specialist in Orange, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Rezazadeh Kalebasty performed 980 Medicare services across 264 unique beneficiaries.

Between the years covered by Open Payments, Dr. Rezazadeh Kalebasty received a total of $626,929 from 37 pharmaceutical and/or device companies across 573 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Rezazadeh Kalebasty is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ 980 Medicare services $626,929 industry payments

Medicare Practice Summary

Medicare Utilization ↗
980
Medicare services
Bottom 49% in CA for hematology & oncology
264
Unique beneficiaries
$117
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~52 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
 886 $118 $633
New patient office visit, complex (60-74 min) 53 $142 $797
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
 41 $75 $430
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$626,929
Total received (2018-2024)
Avg $89,561/year across 7 years
Top 2% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
37
Companies
573
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$576,857 (92.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$48,643 (7.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,429 (0.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$70,677
2023
$38,069
2022
$41,907
2021
$43,600
2020
$82,536
2019
$159,008
2018
$191,132

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Exelixis Inc.
$33,215
Janssen Biotech, Inc.
$28,306
Sumitomo Pharma America, Inc.
$3,488
Bayer Healthcare Pharmaceuticals Inc.
$3,470
Eisai Inc.
$2,063
Aveo Pharmaceuticals, Inc.
$134
Top 3 companies account for 92.0% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$105,082
Exelixis Inc.
$101,369
Janssen Biotech, Inc.
$85,015
GENZYME CORPORATION
$54,046
Janssen Scientific Affairs, LLC
$53,295
EMD Serono, Inc.
$39,762
PFIZER INC.
$34,843
Eisai Inc.
$27,301
EISAI INC.
$23,922
Bayer HealthCare Pharmaceuticals Inc.
$20,925
AstraZeneca Pharmaceuticals LP
$13,887
Amgen Inc.
$10,802
Astellas Pharma US Inc
$7,396
Merck Sharp & Dohme Corporation
$7,305
Novartis Pharmaceuticals Corporation
$5,390
F. Hoffmann-La Roche AG
$5,390
Genentech USA, Inc.
$4,494
Bayer Healthcare Pharmaceuticals Inc.
$4,406
AVEO Pharmaceuticals, Inc.
$3,829
Sumitomo Pharma America, Inc.
$3,488
Seagen Inc.
$3,240
Gilead Sciences, Inc.
$3,120
Immunomedics, Inc.
$2,475
Janssen Global Services, LLC
$1,925
Aveo Pharmaceuticals, Inc.
$1,534
Myovant Sciences Inc.
$1,280
Celgene Corporation
$600
Foundation Medicine, Inc.
$143
Telix Pharmaceuticals
$141
Dendreon Pharmaceuticals LLC
$131
Kite Pharma, Inc.
$124
SANOFI-AVENTIS U.S. LLC
$85
Mirati Therapeutics, Inc.
$64
Genentech, Inc.
$57
MEDIVATION FIELD SOLUTIONS LLC
$24
Rigel Pharmaceuticals, Inc.
$19
Janssen Research & Development, LLC
$18
Top 3 companies account for 46.5% of all-time payments
Associated products mentioned in payments ›
BALVERSA · BAVENCIO · Bavencio · CABOMETYX · Cabometyx · DARZALEX · ERLEADA · Erleada · FOTIVDA · FOUNDATIONONE · ILLUCCIX · IMFINZI · INLYTA · JEVTANA · KEYTRUDA · KRAZATI · Lenvima · NO PRODUCT DISCUSSED · Nubeqa · OPDIVO · ORGOVYX · PADCEV · PROVENGE · Prolia · RYBREVANT · SUTENT · TECENTRIQ · Tavalisse · Trodelvy · XGEVA · XTANDI · Xofigo · Yescarta · ZALTRAP
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (92%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for hematology & oncology in CA.

Looking for a hematology & oncology specialist in Orange?
Compare hematology & oncology specialists in the Orange area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
243
Per 100K population
7.7
County median income
$113,702
Nearest hospital
PROVIDENCE ST. JOSEPH HOSPITAL
0.0 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment ✓ PECOS Monthly updates
Practice Data ✓ Medicare Util. Annual (CY lag)
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Rezazadeh Kalebasty is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 2% of CA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Rezazadeh Kalebasty experienced with office visit, established patient, complex (40-54 min)?
Based on Medicare claims data, Dr. Rezazadeh Kalebasty performed 886 office visit, established patient, complex (40-54 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rezazadeh Kalebasty receive payments from pharmaceutical companies?
Yes. Dr. Rezazadeh Kalebasty received a total of $626,929 from 37 companies across 573 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rezazadeh Kalebasty's costs compare to other hematology & oncology specialists in Orange?
Dr. Rezazadeh Kalebasty's average Medicare payment per service is $117. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rezazadeh Kalebasty) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Hematology & Oncology Specialists in Orange
Browse hematology & oncology specialists in Orange ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Exelixis Inc. Payments to Doctors
See all physicians who received payments from Exelixis Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →